Industry Perspectives on Ophthalmic Opportunities
Gain insight on how industry thinks about a dry eye opportunity, or a cross-linking opportunity, or a uveitis opportunity. The discussion is about no so much what they liked and didn’t like about the earlier presentations at OIS@ASCRS, but in general, what does a company have to do to get their attention, take a deeper look, and maybe even do a partnership or a deal.
Moderator:
![Emmett-Cunningham](https://ois.net/wp-content/uploads/2015/10/emmett-cunningham.jpg)
Emmett T. Cunningham Jr., MD, PhD, MPH
Dr. Cunningham joined Clarus Ventures with 20+ years in the biomedical and biopharmaceutical sectors. Prior, Dr. Cunningham was the SVP, Medical Strategy at Eyetech Pharmaceuticals.
Panelists:
![Laurent-Attias](https://ois.net/wp-content/uploads/2015/12/Laurent-Attias-2016.jpg)
Laurent Attias
Laurent Attias is Senior Vice President, Head of Strategy, BD&L and M&A. In this role, Mr. Attias leads the development of Alcon’s long-term strategic plan.
![Quinton Oswald](https://ois.net/wp-content/uploads/2015/12/Paul-Mclean.jpg)
Quinton Oswald
Quinton Oswald is the CEO of Neurotech. Prior to joining Neurotech, he served as the CEO of SARcode Bioscience, a San Francisco-based biotech that developed lifitegrast, an investigational product for dry eye disease.
![Calvin Roberts](https://ois.net/wp-content/uploads/2015/12/Calvin-Roberts.jpg)
Calvin W. Roberts, MD
Calvin W. Roberts, MD, is Executive Vice President and the Chief Medical Officer at Bausch + Lomb. A specialist in cataract and refractive surgery, Dr. Roberts is credited with developing surgical therapies, over-the-counter products for vision care, prescription ocular therapeutics, and innovative treatment regimens.
![Jane Rady](https://ois.net/wp-content/uploads/2015/12/Jane-Rady.jpg)
Jane E. Rady
Jane Rady is DVP, Business Development for AMO. She joined AMO in 2002 as a corporate officer serving in various capacities.